Criteria for the administration of systemic antimicotic therapy in surgical intensive care units (literature review)

This review focuses on the practical aspects of prevention and treatment of fungal infections in surgical patients. It covers epidemiology and risk factors for invasive candidiasis, updates on the etiological structure of fungal infections in patients in critical conditions, and provides the information on drug sensitivity of Candida species. The authors discuss the limitations of cultural and non-cultural diagnostic methods used in invasive candidiasis, emphasizing the importance of analyzing the existing risk factors in combination with a comprehensive assessment of clinical and laboratory data for timely initiation of adequate antifungal therapy. The review provides a brief description of currently available antimicotics, including polyenes, triazoles, and echinocandins. It also describes the benefits of anidulafungin, which does not interact with other drugs and has no negative effect on the liver and kidney. The article also covers indications for antifungal agents in surgical intensive care units in accordance with international and Russian guidelines. A cohort of patients with abdominal diseases requiring preventive and empirical treatment with antimicotics is described. In additions to that, the manuscript contains a rationale for the use of echinocandins in targeted therapy of invasive candidiasis.

[1]  J. Timsit,et al.  The current treatment landscape: candidiasis. , 2016, The Journal of antimicrobial chemotherapy.

[2]  J. Sobel,et al.  Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  R. Schmid,et al.  Fungal “colonisation” is Associated with Increased Mortality in Medical Intensive Care Unit Patients with Liver Cirrhosis , 2015, Mycopathologia.

[4]  M. Bassetti,et al.  An Italian consensus for invasive candidiasis management (ITALIC) , 2014, Infection.

[5]  Nicolas Papon,et al.  Emerging and Emerged Pathogenic Candida Species: Beyond the Candida albicans Paradigm , 2013, PLoS pathogens.

[6]  T. Calandra,et al.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  T. Calandra,et al.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[8]  F. Grenouillet,et al.  Candida spp. with Acquired Echinocandin Resistance, France, 2004–2010 , 2012, Emerging infectious diseases.

[9]  J. Vincent,et al.  European expert opinion on the management of invasive candidiasis in adults. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[10]  Jacques Bille,et al.  Diagnosis of invasive candidiasis in the ICU , 2011, Annals of intensive care.

[11]  R. Bellomo,et al.  Acquired bloodstream infection in the intensive care unit: incidence and attributable mortality , 2011, Critical care.

[12]  J. Perfect,et al.  Early treatment of candidemia in adults: a review. , 2011, Medical mycology.

[13]  J. Sobel,et al.  Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit , 2011, Mycoses.

[14]  R. Drew,et al.  Echinocandin pharmacodynamics: review and clinical implications. , 2010, The Journal of antimicrobial chemotherapy.

[15]  Jordi Rello,et al.  International study of the prevalence and outcomes of infection in intensive care units. , 2009, JAMA.

[16]  J. Rello,et al.  Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units. , 2009, International journal of antimicrobial agents.

[17]  M. Ghannoum,et al.  Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[18]  J. Nolla,et al.  Fungal colonization and/or infection in non-neutropenic critically ill patients: results of the EPCAN observational study , 2009, European Journal of Clinical Microbiology & Infectious Diseases.

[19]  M. Ellis New dosing strategies for liposomal amphotericin B in high-risk patients. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[20]  R. Hay,et al.  A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  M. Falagas,et al.  Candida Albicans Versus Non-Albicans Intensive Care Unit-Acquired Bloodstream Infections: Differences in Risk Factors and Outcome , 2008, Anesthesia and analgesia.

[22]  C. d’Enfert,et al.  Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome , 2008, Intensive Care Medicine.

[23]  K. Garey,et al.  Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  M. Falagas,et al.  Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies , 2006, European Journal of Clinical Microbiology and Infectious Diseases.

[25]  Shane Gillespie,et al.  Attributable mortality of nosocomial candidemia, revisited. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  J. Devlin,et al.  Temporal assessment of Candida risk factors in the surgical intensive care unit. , 2001, Archives of surgery.

[27]  H. Moecke,et al.  Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients , 1997, Intensive Care Medicine.

[28]  R. Auckenthaler,et al.  Candida Colonization and Subsequent Infections in Critically III Surgical Patients , 1994, Annals of surgery.

[29]  J. Perfect,et al.  Resistance to Antifungal Agents: Mechanisms and Clinical Impact , 2008 .

[30]  R. Barnes Early diagnosis of fungal infection in immunocompromised patients. , 2008, The Journal of antimicrobial chemotherapy.